FASTER Act

House Bill

H.R. 5575

119th Congress

FASTER Act

In Committee

Introduced:Sep 26, 2025

Primary Sponsor

Lauren Underwood

Representative

Democratic

IL-14

Cosponsors

0

Quick Stats

Policy Area

Health

Summary

The FASTER Act aims to increase the domestic production of essential medicines, medical countermeasures, and critical ingredients. It requires the federal government to develop a strategy for boosting domestic manufacturing. The bill also mandates warning labels on drugs made in countries with systemic manufacturing problems, and limits the ability to waive preferences for these crucial medical products in government procurement.

Latest Action

Referred to the Subcommittee on Health.

SponsorLauren Underwood (D-IL)

Introduced9/26/2025

StatusReferred to the House Committee on Science, Space, and Technology.

ChamberHouse

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

FASTER Act

The FASTER Act aims to increase the domestic production of essential medicines, medical countermeasures, and critical ingredients. It requires the federal government to develop a strategy for boosting domestic manufacturing. The bill also mandates warning labe

Community Breakdown

Pass

0%

Fail

0%

0 predictions

The FASTER Act aims to increase the domestic production of essential medicines, medical countermeasures, and critical ingredients. It requires the federal government to develop a strategy for boosting domestic manufacturing. The bill also mandates warning labels on drugs made in countries with systemic manufacturing problems, and limits the ability to waive preferences for these crucial medical products in government procurement.

Bill Number: 5575
Sponsor: Lauren Underwood (D-IL)
Introduced: 9/26/2025
Status: Referred to the House Committee on Science, Space, and Technology.
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: FASTER Act
Bill Number: 5575
Sponsor: Lauren Underwood (D-IL)
Status: Referred to the House Committee on Science, Space, and Technology.
Introduced: 9/26/2025
Summary: The FASTER Act aims to increase the domestic production of essential medicines, medical countermeasures, and critical ingredients. It requires the federal government to develop a strategy for boosting domestic manufacturing. The bill also mandates warning labels on drugs made in countries with syste

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

The FASTER Act aims to increase the domestic production of essential medicines, medical countermeasures, and critical ingredients. It requires the federal government to develop a strategy for boosting domestic manufacturing. The bill also mandates warning labels on drugs made in countries with systemic manufacturing problems, and limits the ability to waive preferences for these crucial medical products in government procurement.

Last updated: 12/29/2025

Official Summary

Congressional Research Service summary

Safe Medicine Act This bill addresses issues related to the manufacture of drugs, including essential medicines. The Department of Health and Human Services, the Department of Defense, and the Department of Veterans Affairs must jointly develop and implement a strategy to increase the domestic production of essential medicines, medical countermeasures, and critical inputs. If the Food and Drug Administration determines that a drug or active pharmaceutical ingredient is manufactured in a country that may be producing contaminated drugs or ingredients due to systemic manufacturing-related problems, the labeling for that drug or ingredient must have a boxed warning about the potential for contamination. For government procurement purposes, the President's authority to waive certain purchasing requirements that discriminate against foreign products may not be used to waive any preferences for goods that are essential medicines, medical countermeasures, or critical inputs.

Key Points

Main provisions of the bill

Requires federal agencies to develop a strategy for increasing domestic production of essential medicines and critical medical supplies
Mandates warning labels on drugs made in countries with manufacturing issues that could lead to contamination
Limits the ability of the President to waive preferences for government procurement of essential medicines and supplies

How This Impacts Americans

Potential effects on citizens and communities

If passed, this bill would impact American consumers of prescription drugs and medical products, as well as the pharmaceutical industry and government procurement officials. It could help ensure a more reliable domestic supply of crucial medicines, but may also increase costs for consumers and the government. Healthcare providers and patients would benefit from greater transparency about potential manufacturing problems in other countries.

Policy Areas

Primary Policy Area

Health

Related Subjects

Cardiovascular and respiratory health

Chemical and biological weapons

Drug safety, medical device, and laboratory regulation

Drug therapy

Emergency medical services and trauma care

Health technology, devices, supplies

Infectious and parasitic diseases

Manufacturing

Medical tests and diagnostic methods

Military medicine

+7 more

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

5575, 119th Congress (2025). "FASTER Act". Source: Voter's Right Platform. https://votersright.org/bills/118-hr-5575

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.

Related Bills in Health

HR 3021

Empowering Patient Choice of Medical Care Act

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

HR 2111

To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.

Referred to the House Committee on Energy and Commerce.

HR 2884

Anti-Racism in Public Health Act of 2025

Referred to the House Committee on Energy and Commerce.

S 1406

SOAR Act of 2025

Read twice and referred to the Committee on Finance.